Recruiting Cancer Clinical Trials

ABBIL1TY

A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)
Description: This trial is testing a new combination of cancer drugs to treat advanced non-small cell lung cancer (NSCLC) in people whose cancer has come back or worsened after previous treatments.
Study Phase: Phase 2
Principal Investigator: Dr Sinead Cuffe
Further information

HARMONi-3 (SMT112-3003)

A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer
Description: 1st Line Metastatic Squamous NSCLC
Study Phase: Phase 3
Principal Investigator: Prof Patrick Forde
Further information

Krystal-4

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Description: This study is testing a new combination of medicines to treat a specific type of lung cancer called non-small cell lung cancer (NSCLC). It focuses on patients who: Have not yet received treatment for their advanced lung cancer. Have a KRAS G12C mutation, which is a change in a gene that can cause cancer cells to grow.
Study Phase: Phase 2
Principal Investigator: Dr Sinead Cuffe
Further information

Krystal-7

A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Description: This trial is recruiting patients with advanced lung cancer . The cancer must have a particular mutation called KRAS G12C. Patients will either receive a new drug called MRTX849 alone or in combination with pembrolizumab
Study Phase: Phase 2
Principal Investigator: Sinead Cuffe
Further information

MK-2870-023

A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer
Description: To compare pembrolizumab with or without maintenance MK-2870 with respect to Overall Survival (OS) Hypothesis (H1): Pembrolizumab with maintenance MK-2870 is superior to pembrolizumab without maintenance MK-2870 with respect to OS To compare pembrolizumab with or without maintenance MK-2870 with respect to PFS per RECIST 1.1 as assessed by BICR Hypothesis (H2): Pembrolizumab with maintenance MK-2870 is superior to pembrolizumab without maintenance MK-2870 with respect t
Study Phase: Phase 3
Principal Investigator: Dr. Sinead Cuffe
Further information

NeoCoast-2

A Phase 2 Open-label, Multicenter, Randomized, Study of Neoadjuvant and Adjuvant Treatment in Subjects with Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer (NeoCOAST-2)
Description: NeoCOAST-2 is a Phase 2 clinical trial testing new combinations of medicines to treat early-stage non-small cell lung cancer (NSCLC) that can be removed with surgery. The goal is to improve outcomes by giving treatment before and after surgery.
Study Phase: Phase 2
Principal Investigator: Prof Patrick Forde
Further information

RELATIVITY (CA224-1093)

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression ≥ 1%
Description: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide, accounting for approximately 18% of all cancer deaths. The introduction of immune checkpoint inhibitors targeting the PD-1 signaling pathway in the treatment of patients with NSCLC has had a significant effect on patient survival. Pembrolizumab combined with chemotherapy in the front-line setting has shown an improvement in overall survival (OS) in NSCLC patients compared to chemotherapy alone.
Study Phase: Phase 3
Principal Investigator: Dr. Sinead Cuffe
Further information